$XGN

EXAGEN INC. (XGN): Submission of Matters to a Vote of Security Holders

EXAGEN INC. (XGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. exdx-20260609 0001274737 FALSE 0001274737 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Original reporting
Published Jun 9, 2026, 8:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$XGN
Neutral
high confidence
Mentioned
$XGN
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XGNNeutralLow
01

Why it matters

Confirms the election of two Class I directors, ratification of BDO USA as independent auditor for 2026, and an advisory approval of executive compensation.

02

Market read

Traders may treat this as a confirmation/housekeeping disclosure; it typically does not change valuation drivers absent a surprise outcome.

03

What to watch

The filing does not disclose whether any proposal faced meaningful opposition beyond a few votes against/withheld; without context from the proxy, market interpretation may be limited.

Relevance 6/10Novelty 2/10Timing: after-hours / filed June 9, 2026

Background

Item 5.07 of Form 8-K reports final results of stockholder votes from the company’s annual meeting.

Company-level read

Ticker impact

$XGNNeutralHigh confidence
Context

Exagen filed an 8-K confirming final vote results from its June 9, 2026 annual meeting, including director elections and auditor ratification.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless votes imply governance/audit changes beyond expectations.

Evidence & confidence

The filing is a standard post-meeting tabulation (Item 5.07) with no new financial guidance, deal, litigation, or operational change described.

Market effects

Minimal; governance vote outcomes do not reset sector expectations.

Minimal; US-listed microcap governance filing.

Minimal; no cross-border transaction or regulatory action mentioned.

Counterpoint

If investors were uncertain about auditor continuity or board composition, the final vote totals could reduce uncertainty and modestly support sentiment.

Key entities

  • Exagen Inc.

    Nasdaq-listed issuer filing the 8-K with final annual meeting vote results.

  • BDO USA, P.C.

    Independent registered public accounting firm ratified for the fiscal year ending Dec. 31, 2026.

  • Tina S. Nova, Ph.D.

    Elected Class I director for a three-year term (final vote totals reported).

  • Scott Kahn, Ph.D.

    Elected Class I director for a three-year term (final vote totals reported).

Related articles

$XGNMedAI 8/10

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.

$XGNMedAI 8/10

Exagen Inc. Q2 2026 Earnings Call Summary

Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.

$XGNMed

EXAGEN INC. (XGN): Results of Operations and Financial Condition

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026exagenearningspressr.htm EX-99.1 Document Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased

$LLYMedAI 8/10

Eli Lilly launches oral weight-loss pill in UK pharmacies

Eli Lilly (NYSE:LLY) has launched its oral weight-loss and diabetes pill, Foundayo, in UK pharmacies. Approved by the Medicines and Healthcare products Regulatory Agency, it is available via private prescription. The UK is the first European country to authorize the tablet for these uses. Foundayo is prescribed for adults with specific BMI criteria and can be taken at any time of day. It mimics the GLP-1 hormone to reduce hunger and improve blood sugar control. Common side effects include nausea

$9984.THighAI 8/10

SoftBank Group deepdive: What risks does the latest $6 bln bond sale carry?

SoftBank Group's stock fell 5.33% after announcing a ¥1 trillion ($6.3 billion) bond sale to fund OpenAI investments. Total debt surged 57% to ¥25.4 trillion, while EBITDA dropped 43% and free cash flow reached -¥2.16 trillion. The company's current ratio is 0.8x, indicating short-term liquidity concerns. Investors are worried about the company's high debt levels and uncertain returns on AI investments.